# 1. Financial Performance ## A. Key Figures * **Revenue:** ₹2,567 Cr Q2 FY'26 (+5% YoY) · ₹5,182 Cr H1 FY'26 (+8% YoY) * **PBT:** ₹125 Cr Q2 FY'26 (flat) · ₹313 Cr H1 FY'26 (+14% YoY, ex-nonrecurring) * **Gross Margin:** 44% (near 4–5 year high) * **Net Profit Margin:** 5% * **Blended EBIT/tonne:** ₹1,750 H1 (below ₹1,900–2,000 guidance) · **Underlying EBIT/tonne:** ₹2,006 Q2 FY'26 (+QoQ operational improvement) ## B. Revenue Growth * **Divergent Segment Performance:** Consolidated revenue growth accelerated in H1 despite flat Q2, while CDMO revenues collapsed to **₹13 Cr**, with normalization uncertain amid incomplete client visibility. ## C. Profitability Trends * **Healthy Underlying Earnings Momentum:** Bottom-line growth remains robust YTD, driven by value-added business investments and **operational EBIT/tonne expansion to ₹2,006**, even as reported margins lag due to input cost distortions. * **Cost Pressures & Accounting Noise:** Sharp rise in unallocated expenses and employee costs reflects **variable pay accruals linked to strong profitability**, while tax rate volatility stems from dividend tax accounting, not operational changes. * **Margin Resilience Amid Leverage Constraints:** Despite limited fixed cost absorption from slow top-line growth, gross margin hit a multi-year high of 44%, signaling strong pricing or input management. ## D. Balance Sheet * **Stable Leverage Outlook:** Closing debt expected to remain flat YoY, supported by proactive working capital reduction offsetting investment outflows in H1. ## E. Cash Flow * **Disciplined Working Capital Management:** Tight controls have preserved liquidity, with expectations for sustained discipline limiting incremental borrowing in H2. --- # 2. Segment & Business Mix ## A. Key Figures * Crop Protection Margin: 23.3% * **Animal Feed Volume:** **18% YoY growth** (cattle feed) * **Animal Feed Margin:** **+70 bps YoY** * **Vegetable Oil Revenue:** **41% YoY growth** * Vegetable Oil Margin: 22.4% (expansion) * **Astec LifeSciences Revenue:** **25% YoY decline** * **Enterprise Segment Revenue:** **15% YoY growth** * **CDMO Revenue Mix:** **54%** of total (up from 26% in FY '23) ## B. Crop Protection * **Severe Downturn:** Crop Protection faced a sharp contraction in revenue and profitability due to adverse weather, reduced acreages, and loss of product monopolies. * **Competitive Pressure:** Market share erosion amid **2–3 new entrants** in key products, underperforming a growing industry despite strategic portfolio diversification plans. * **Oil Palm Bright Spot:** Oil palm protection business emerges as a key growth driver with strong current performance and long-term upside potential. ## C. Animal Feed * **Volume-Led Strength:** Cattle feed volumes surged on strong consumption and **geographic expansion**, with volume proving a more reliable metric than revenue due to price pass-through effects. * **Margin Resilience:** Underlying margins improved despite soft commodity prices and higher input costs, supported by **product value additions** and **operational efficiency**. * **Branded Growth:** Value-added dairy products now represent **36% of sales** (up from 32%), and GFL’s overall branded business stands at **85%**, signaling successful premiumization. ## D. Vegetable Oil * **Outperformance Confirmed:** Vegetable Oil emerged as a star performer with robust revenue growth and margin expansion, driven by higher realizations and **improved oil extraction ratio**. ## E. Astec Segments * **Diverging Trends:** Astec LifeSciences revenue fell on weak CDMO demand, while the enterprise segment rebounded with **15% growth** and improved EBITDA on pricing and volume recovery. * **CDMO Structural Shift:** CDMO now constitutes **54% of total revenue** (from 26% in FY '23), with stable **30–31% margins** and sustained client engagement across active projects. --- # 3. Volume & Pricing Trends ## A. Key Figures * **Cattle Feed Volume Growth:** **mid-teens** (+ ~15%) · **50%** of Animal Feed business * **Oil Extraction Ratio:** **19-odd%** (record high) * **Enterprise Revenue Growth:** **~15%** (primarily volume-driven) * **H1-H2 Volume Split:** **65-35** (seasonal production pattern) ## B. Volume Performance * **Strong Volume Momentum:** Animal Feed delivered robust double-digit volume growth in H1, led by mid-teens expansion in cattle feed, which now constitutes half the segment. * **Operational Efficiency Gains:** Record oil extraction ratio achieved due to improved operations and favorable monsoon conditions, boosting yield. * **Demand Normalization:** Volume recovery follows normalization of destocking in key regions, with demand returning to near-sustainable levels. ## C. Pricing Dynamics * **Volume-First Strategy:** Management prioritizes volume over pricing, citing historical unpredictability and volatility in enterprise pricing. * **Positive Feed-Milk Price Link:** Higher milk prices are driving adoption of branded compound feed as farmers invest in productivity, supporting structural demand. --- # 4. Product & Pipeline Progress ## A. New Product Launches * **Strategic Diversification Underway:** Entry into maize with **Ashitaka**, a new herbicide, marks a pivotal shift beyond cotton and chilli, targeting rising acreage and reducing crop concentration risk. * **Accelerated Launch Cadence:** Commercialization pace increasing to **at least 2 new molecules per year**, supported by enhanced R&D, with a **slate of launches planned over the next 6–7 months**. * **Near- and Medium-Term Pipeline Visibility:** A **Q4 launch** of a pan-crop product and **three additional products** scheduled for April–August next year reinforce sustained innovation and derisking. ## B. R&D Pipeline * **R&D as Margin Catalyst:** Life cycle management under **Project PI** drives cost efficiency and product upgrades, directly supporting margin resilience. * **Expanding Molecule Pipeline:** **Around 12 molecules** currently in development, with increased early-stage collaborations extending gestation to **4 years** but aiming for stickier innovator partnerships. * **New Growth Levers Emerging:** **In-licensing initiatives** initiated and agreements in final stages, marking the start of a broader external innovation strategy. ## C. Label Expansion * **Portfolio Optimization via Label Extensions:** Pursuing expanded crop claims for existing products to increase utilization and regulatory reach without new launches, enhancing asset productivity. --- # 5. Capacity & Utilization ## A. Key Figures * **R&D Center Capacity:** **60 fume hoods** (~100 simultaneous reactions) · **~100 reaction steps** infrastructure capacity * **R&D Utilization:** **~90%** current capacity utilization · **100 scientists and staff** * **R&D Pipeline Metrics:** **~120 inquiries** for **12 projects** (10% conversion) · **8-step** average reaction complexity ## B. Plant Utilization * **Significant Utilization Gains:** Plant utilization has doubled versus prior three quarters, with positive trends across all sites and the business now very near breakeven levels. * **Extraction Efficiency:** Operational improvements in harvesting, farmer support, and process loss reduction are driving higher extraction rates. ## C. R&D Capacity * **World-Class R&D as Strategic Lever:** CDMO-focused R&D center, established ~5 years ago, is recognized as comparable to leading Western facilities and serves as a key partnership differentiator. * **Full Pipeline with Commercial Upside:** R&D operations are fully occupied, supporting ~12 molecules in development, with multiple projects expected to commercialize in 1–2 years. * **Stable Team, High Complexity Work:** Despite no recent scaling, the team maintains high output, handling chemistries with **8-step average complexity**, reflecting efficient use of existing capacity. ## D. Project Pipeline * **Growth Pipeline Reinforcement:** Strategic expansion of the business development team to strengthen future CDMO project inflow and offset long lead times. * **Enterprise-Wide Optimization Drive:** Project PI, led by top leadership including Sunil Kataria, is targeting cross-functional cost savings to fund growth, with initiatives active across Astec and other units. --- # 6. Risks & Weather Exposure ## A. Key Figures * **Metric Name:** No significant quantitative financial metrics provided ## B. Monsoon Impact * **Weather-Driven Disruption:** Crop Protection segment faced **narrowed spraying windows** due to uneven and excessive rainfall, leading to a moderately softer H2 outlook. * **Cross-Region Challenges:** Adverse monsoon patterns affected agricultural performance across geographies, with similar conditions impacting Astec’s operations in Brazil. * **Category-Wide Pressure:** Performance decline in legacy products like Hitweed primarily driven by weather constraints, not competitive pricing or margin erosion. * **Offsetting Tailwinds:** Strong monsoon supported higher fresh fruit bunch (FFB) availability, boosting volumes and extraction efficiency in relevant segments. ## C. Crop Acreage Risk * **Input-Specific Downturn:** Reduced chilli acreage—driven by lower crop prices—negatively impacted in-licensed product performance. * **Concentration Vulnerability:** Business remains exposed to external shocks due to over-reliance on key crops like cotton and dominant product categories such as herbicides. ## D. Vendor Discounting * **Margin Reporting Pressure:** Ongoing vendor discounting will continue to weigh on reported EBIT per tonne, though core operational profitability remains intact. * **Sector-Wide Headwinds:** Agrochemical R&D progress hindered over the past two years by delayed supply chain adjustments and slow innovator response. --- # 7. Guidance & Outlook ## A. Key Figures * **FY'26 Revenue Guidance:** **₹500 Cr** turnover target (maintained) · **EBITDA breakeven** expected * **EBIT per Tonne (Adjusted):** **₹2,000** in Q1 & Q2 FY'26 (in line with guidance) * **Agrochemical CDMO Demand:** **55%** of annual demand stable, shift to H2 due to cropping patterns ## B. Full-Year Targets * **Guidance Maintained Amid Sectoral Headwinds:** Despite softer Crop Protection trends and delayed CDMO recovery, company affirms full-year revenue and EBITDA breakeven targets, citing countervailing growth drivers. * **Stabilization Year with Forward Momentum:** FY'26 viewed as a stabilizing phase, with CDMO performance expected to break out in **FY'27** driven by commercialized molecules from the maturing pipeline. * **Margin Resilience & Cost Pressures:** Adjusted EBIT per tonne remains on track; however, **bill discounting expenses** will persist, offset by savings from **Project PI** supporting margin expansion and growth investments. * **Phasing Normalization:** Enterprise-CDMO revenue balance expected to normalize by year-end, reflecting typical seasonality rather than demand shifts. ## C. Strategic Roadmap * **Strategy Refresh Underway:** New leadership with FMCG background driving a 70–90-day strategic review to simplify the **7-business portfolio** and clarify investment and return roles. * **Shift to Value-Added, Consumer-Centric Model:** Clear pivot from commoditized offerings toward **value-added products** in animal feed, foods, and Astec, supported by market-outward go-to-market strategies. * **Building Resilient Growth Pillars:** Objective to transform isolated growth points into multiple, durable growth engines across all units to reduce volatility. ## D. FY '30 Vision * **Long-Term Vision in Development:** Comprehensive **FY'30 roadmap** for Godrej Agrovet and Astec being formulated, incorporating oil palm planting dynamics and portfolio strategy. * **Upcoming Unveiling of 3–4 Year Plan:** Management committed to disclosing the **FY'30 GAVL unleash model** with forward-looking projections by end-March.